Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-04

Study Completion Date

2019-07-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this project is to study the efficacy of triheptanoin oil in patients with GLUT1 deficiency syndrome.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Treatment With UX007 for a Single Patient With GLUT1 Deficiency Syndrome

NCT02968953

Glucose Transporter 1 Deficiency Syndrome

NO_LONGER_AVAILABLE

Antioxidant Signature in Adult Patients With Phenylketonuria

NCT02212288

PKU Hyperphenylalaninemia

COMPLETED

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU Patients

NCT04256655

Phenylketonurias

WITHDRAWN PHASE1

A Safety and Efficacy Study of GTX-102 in Subjects With Deletion- or Nondeletion-type Angelman Syndrome (AS)

NCT07157254

Angelman Syndrome

RECRUITING PHASE2

Triheptanoin (UX007) to Treat Citrate Transporter Deficiency

NCT02500082

Citrate Transporter Deficiency SLC13A5 Gene Mutation

NO_LONGER_AVAILABLE

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of the study is:

\- to evaluate the capacity of triheptanoïn to improve the condition of patients with GLUT1-DS

The secondary objectives of the study are:

* to confirm the short-term safety of triheptanoïn therapy in patients with GLUT1-DS
* to evaluate the short-term effects of triheptanoïn treatment on motor function, autonomy, quality of life and clinical signs of patients with GLUT1-DS
* to evaluate the effect of triheptanoïn on brain energy metabolism using non-invasive 31P-MRS spectroscopy after activation of the occipital cortex in order to measure the levels of high-energy phosphates (such as ATP and phosphocreatine)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glut1 Deficiency Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GLUT1 DS

Group Type EXPERIMENTAL

GLUT1 DS

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GLUT1 DS

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mutation in SLC2A1 gene
* Age \> 3 years
* Patient with history/frequency of seizures or movement disorders documented at least 3 months prior to the beginning of the study
* Covered by french social security
* Patients who freely agree to participate in this study and understand the nature, risks and benefits of this study and give their written informed consent. (In addition to the requirement for the consent of parents or the legal representative, adolescents can provide additional informed consent to participate in clinical trials)

Exclusion Criteria

* Evidence of psychiatric disorder
* Attendant neurological disorder
* Comorbid medical condition that would render them unsuitable for the study, e.g. HIV, diabetes
* Pregnant or parturient or lactating women
* Unwillingness to be informed in case of abnormal MRI
* Failure to give written informed consent
* Unable to understand the protocol
* Unable to participate to the whole study
* Absence of signed informed consent
* Persons deprived of their liberty by judicial or administrative decision
* Person subject to an exclusion period for another research

Minimum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No